Silver Book Fact

Effectiveness of pacemaker/defibrillators to control AFib

Widespread use of pacemaker/defibrillators to control atrial fibrillation could result in a 50% decrease in stroke.

Shekelle P, Ortiz E, Newberry S, Rich M, et al. Identifying Potential Health Care Innovations for the Elderly of the Future: Health and costs of the future elderly. Health Aff. 2005; 24(2). https://www.ncbi.nlm.nih.gov/pubmed/16186152

Reference

Title
Identifying Potential Health Care Innovations for the Elderly of the Future: Health and costs of the future elderly
Publication
Health Aff
Publication Date
2005
Authors
Shekelle P, Ortiz E, Newberry S, Rich M, et al
Volume & Issue
Volume 24, Issue 2
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Cost-savings associated with Warfarin use in AFib patients
    Warfarin use in Medicare patients with nonvalvular atrial fibrillation was independently associated with lower medical costs averaging $9,836 per patient, per year.  
  • Cost of warfarin therapy for AFib patients
    In patients with nonvalvular atrial fibrillation (AF) and one additional stroke risk factor, warfarin therapy cost $8,000 per quality-adjusted life-year (QALY) saved.  
  • Aspirin use in AFib patients
    Meta-analysis of a number of randomized controlled trials found that aspirin use in atrial fibrillation patients reduced stroke risk by an average 22%.  
  • Stroke risk reduction from thrombin inhibitor in AFib patients
    A recently approved direct thrombin inhibitor was found to reduce the risk of stroke/peripheral embolic events in atrial fibrillation patients by 34%, and the risk of hemorrhagic stroke by 74%—compared…  
  • Effects of optimal anticoagulation among AFib patients
    If 50% of individuals with atrial fibrillation who do not receive prophylaxis were optimally anti-coagulated, 19,380 emboli would be prevented and $1.1 billion would be saved each year.